The big pharma company will no longer progress emugrobart to late-stage trials in FSHD and SMA due to a lack of efficacy.

The company discontinued developing emugrobart after two studies showed the drug didn’t achieve intended outcomes.

Mice flown aboard the International Space Station and exposed to Mars-like gravity for roughly a month showed only partial ...

Loss of muscle mass, also called muscle wasting or atrophy, can happen gradually as part of getting older or more suddenly due to underlying medical conditions. Other factors can contribute, like ...

It's well known that spaceflight causes muscle atrophy and other biological changes in reduced gravity, and especially in ...

In a letter to European patients, Roche said its decision to end development of “emugrobart” was based on the drug “not ...

Skeletal muscle atrophy, or wasting, is a devastating and often irreversible syndrome during the aging process and for patients with advanced cancer. Muscle wasting involves a decrease in muscle mass ...

Cancer cachexia is a multifactorial syndrome marked by a severe loss of body weight due primarily to the wasting of skeletal muscle and adipose tissue. This syndrome is often accompanied by systemic ...

A team of researchers believes that pythons may contain clues to help treat a range of human ailments — from heart disease to muscle atrophy, and more.

HOUSTON – A newly identified gene, atrogin-1, is involved in muscle loss associated with cancer, diabetes, fasting and kidney disease as well as in the atrophy occurring with disuse, inactivity, and ...

Late-stage trial data for Roche’s drug against muscle-wasting Elevidys showed positive results after two years of treatment for male patients aged 4 or older with Duchenne muscular dystrophy. The data ...